
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc's strong financial outlook is supported by significant gross margin expansion, which has improved from the low 40s to approximately 60%, driven by the successful mix of higher-priced tests like Signatera and expanded payor reimbursements. The company has demonstrated robust revenue growth, increasing nearly six-fold since 2019, positioning itself favorably within the $30 billion cancer screening total addressable market (TAM) alongside its dominance in non-invasive prenatal testing (NIPT) and minimal residual disease (MRD) testing. Furthermore, the anticipated growth in Medicare Advantage reimbursement rates for Signatera, projected to reach the mid-to-high 60% range by the end of 2024, underscores Natera's potential for continued revenue growth and enhanced market coverage.
Bears say
Natera Inc faces significant risk to its revenue streams and overall path to profitability due to potential reductions in reimbursement from payors for its diagnostic products and services. Additionally, ongoing compression of average selling prices (ASP) for products like Panorama is likely to further erode margins, raising concerns about sustainable profitability. Finally, potential delays in clinical trial results and logistical challenges could hinder the company's long-term revenue growth projections, contributing to a negative outlook on its financial stability.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares